• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference

    Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference

  2. UPDATE: Tenet climbs on deal; Carnival, Biogen dip on downgrades

    UPDATE: Tenet climbs on deal; Carnival, Biogen dip on downgrades

  3. Street gushes over Alzheimer's drug, but some worry about overreaction

    Street gushes over Alzheimer's drug, but some worry about overreaction

  4. UPDATE: Nike jumps on earnings; Tiffany struggles with dollar headwinds

    UPDATE: Nike jumps on earnings; Tiffany struggles with dollar headwinds

  5. Biogen's stock falls on first day with new name after analyst downgrade

    Biogen's stock falls on first day with new name after analyst downgrade

  6. MARKET SNAPSHOT: Nasdaq Punches Past 5,000 As Stocks Score Big Weekly Gains

    MARKET SNAPSHOT: Nasdaq Punches Past 5,000 As Stocks Score Big Weekly Gains

  7. UPDATE: Chesapeake shares rise after capex budget trimmed

    UPDATE: Chesapeake shares rise after capex budget trimmed

  8. UPDATE: U.S. stocks rise, on pace for strong weekly jump

    UPDATE: U.S. stocks rise, on pace for strong weekly jump

  9. MARKET SNAPSHOT: U.S. Stocks Rise, On Pace For Strong Weekly Jump

    MARKET SNAPSHOT: U.S. Stocks Rise, On Pace For Strong Weekly Jump

  10. UPDATE: U.S. stocks rise, on pace for strong weekly jump

    UPDATE: U.S. stocks rise, on pace for strong weekly jump

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.